Integra LifeSciences (IART) Set to Announce Earnings on Monday

Integra LifeSciences (NASDAQ:IART) is scheduled to issue its quarterly earnings data before the market opens on Monday, May 6th. Analysts expect the company to announce earnings of $0.55 per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.01). Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The firm had revenue of $397.00 million during the quarter, compared to analyst estimates of $399.30 million. During the same period in the previous year, the firm posted $0.94 EPS. The company’s revenue for the quarter was down .3% compared to the same quarter last year. On average, analysts expect Integra LifeSciences to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Integra LifeSciences Trading Down 0.2 %

NASDAQ IART opened at $28.34 on Monday. Integra LifeSciences has a 12 month low of $27.18 and a 12 month high of $56.21. The company has a 50-day moving average of $35.34 and a 200-day moving average of $38.77. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.45 and a quick ratio of 2.18. The company has a market cap of $2.23 billion, a P/E ratio of 34.14, a P/E/G ratio of 0.85 and a beta of 1.12.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. JMP Securities dropped their price objective on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a research note on Thursday, February 29th. Truist Financial dropped their price objective on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a research note on Friday, March 1st. Citigroup raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price objective for the company in a research note on Wednesday, April 3rd. Finally, StockNews.com downgraded shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Friday, April 5th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Integra LifeSciences has an average rating of “Hold” and an average price target of $44.89.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.